Last reviewed · How we verify
NCT02225184
Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans
trial in Genetic Underpinning of Substance Abuse in 81 participants. Completed in 31 December 2018.
31 December 2018
Quick facts
| Lead sponsor | National Institute on Drug Abuse (NIDA) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 81 |
| Start date | 23 August 2014 |
| Primary completion | 31 December 2018 |
| Estimated completion | 31 December 2018 |
| Sites | 1 location across United States |
Conditions studied
- Genetic Underpinning of Substance Abuse — all drugs for Genetic Underpinning of Substance Abuse →
- Polymorphism-genetic — all drugs for Polymorphism-genetic →
- Drug Abuse/Dependence — all drugs for Drug Abuse/Dependence →
- Opiod-Related Disorders — all drugs for Opiod-Related Disorders →
Sponsor
National Institute on Drug Abuse (NIDA)
Who can join
18 and older, any sex, with Genetic Underpinning of Substance Abuse or Polymorphism-genetic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: \- Differences in peoples genes can make them respond to drugs in different ways. Methadone and buprenorphine are two drugs used to treat drug addiction. A study showed that African Americans with a certain genetic marker did better using one kind of drug treatment over the other. Researchers want to see if they can repeat these findings. They also want to study other things that affect how well people do in treatment. Objective: \- To see if certain genetic markers and other facts about a person s life can predict how well they do in treatment for addiction to opioids and cocaine. Eligibility: \- African American adults age 18 and over. They must be former or current participants in an Archway Treatment Clinic study. They must have been on a stable dose of either study drug for at least 12 weeks. They also must have given urine samples regularly for at least 10 weeks. Design: * Participants will come to the clinic for 1 visit lasting about 2 hours. * Participants will give 1 teaspoon of blood for genetic testing. They will be asked if their sample can be used in future studies. * If researchers cannot get enough blood, they will do a cheek swab. This will collect skin cells for genetic testing. * Participants will fill out 3 questionnaires. * Results of genetic testing and answers to questionnaires will be kept private.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02225184
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Institute on Drug Abuse (NIDA) trials
Trials by the same sponsor.
- NCT07468552 — Trial of Tirzepatide for the Treatment of Cannabis Use Disorder · Phase 2 · not yet recruiting
- NCT06808932 — VK4-116 Phase I Study With Food-Effect · Phase 1 · not yet recruiting
- NCT06676059 — SMART-r: Substance Monitoring and Active Relapse Tracking Repository · recruiting
- NCT06577454 — Measuring the Effects of Neurostimulation on Risky and Ambiguous Decision-Making Capacity in People With and Without Sub · NA · suspended
- NCT06868914 — Phase I Trial of High-Density Theta Burst Stimulation (hdTBS) · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02225184 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA)
- Last refreshed: 3 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02225184.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing